Cybin’s CYB003 has been in Phase 3 for major depression since the end of 2024, so the news is not that it entered. Entry was never the milestone that mattered anyway: reaching Phase 3 is the precondition for an FDA submission, not evidence a drug will clear it. The development that does matter is that the entering is nearly over. The lead study in CYB003’s three-trial pivotal program has a primary completion estimate of August 2026, which puts the first Phase 3 readout for a deuterated psilocin in depression months away rather than years. How the molecule is positioned heading into that readout says more about where the field is competing than any mechanism slide could. CYB003 is a psilocybin-class psychedelic, the same broad mechanism as Compass Pathways’ COMP360, and it is not trying to win on that mechanism. It is trying to win on the clock, the dose schedule, and the size of the patient population it is allowed to address.
What CYB003 is
CYB003 is a synthetic, deuterated isotopomer of psilocin, the active metabolite that psilocybin converts into in the body. Deuteration, the substitution of deuterium for hydrogen at specific positions, alters how quickly the molecule is metabolized, and Cybin’s stated purpose is to produce a more predictable and shorter pharmacokinetic profile than psilocybin itself. In practice that means a shorter duration of acute psychedelic effects. The program, branded PARADIGM, comprises three Phase 3 trials: APPROACH, a roughly 220-patient study that began at the end of 2024 with primary completion expected in August 2026; EMBRACE, a multicenter study of around 330 patients comparing two active doses against placebo, recruiting since late 2025; and EXTEND, a long-term extension. Phase 2 results reported significant symptom improvement, high remission rates, and no serious adverse events, which is the basis for the Phase 3 design.
One detail in that design matters more than the trial count. CYB003 is being tested as an adjunctive treatment, given on top of a stable antidepressant in patients with moderate-to-severe depression who have had an inadequate response, defined as less than 50 percent improvement. That is a different and broader population than the one Compass is pursuing.
Three axes of differentiation, none of them mechanism
Read against COMP360, CYB003 differentiates on three things, and the mechanism is not among them.
The first is duration. A core practical barrier to psilocybin therapy is that the acute experience lasts roughly six to eight hours, which means a dosing session ties up a clinic room and trained monitors for most of a day. A molecule engineered for a shorter trip is a molecule engineered for a shorter, cheaper, more schedulable session. That is the explicit point of the deuteration strategy, and it is an operations argument, not a biology one.
The second is population. Compass has run COMP360 in treatment-resistant depression, a narrower and more severe group. CYB003’s Phase 3 targets major depressive disorder with inadequate antidepressant response as an adjunct, a larger addressable population. Defining the indication more broadly expands the potential market, at the cost of competing in a population where the placebo response tends to run higher, which is the recurring difficulty in any depression trial.
The third is predictability. Cybin frames the deuterated profile as more consistent than psilocybin’s, which, if it holds, eases dosing standardization across sites. This too is a deployability claim.
The questions Phase 3 still has to answer
None of the differentiation removes the hard parts. CYB003 is a 5-HT2A psychedelic, and the issues that attend the whole class apply to it. The adjunctive design, layering the drug on patients already taking an antidepressant, is harder to read than a clean monotherapy design, because any drug-placebo separation has to emerge on top of an existing treatment. The functional-unblinding problem, in which participants and raters can tell who received an active psychedelic and that knowledge inflates apparent effects, is not solved by shortening the trip; a shorter psychedelic experience is still a recognizable one. And the Phase 2 remission rates that justify the program are exactly the kind of early-stage figures that the placebo dynamics of a larger Phase 3 can compress.
There is also the durability question that the third trial, the extension study, exists to probe. The commercial logic of psychedelic therapy is that a small number of dosing sessions produces lasting benefit. Whether CYB003’s effect persists is what EXTEND is built to test, and it is the property that determines whether the shorter session is a genuine advantage or just a cheaper version of an effect that fades.
What it signals
The useful read is not that Cybin has a better psychedelic than Compass. It is that the second company into Phase 3 chose to compete on session length, dosing convenience, and addressable population rather than on the molecule’s mechanism, because the mechanism is no longer where the contest is. The barrier to psychedelic therapy reaching scale was never that psilocybin does not do anything to the brain. It was that delivering it is slow, expensive, and operationally heavy. CYB003 is a bet that the program which makes the treatment easiest to deliver, not the one with the most novel biology, is the program that wins. Whether the bet pays off depends on Phase 3 data that, for the lead study, is due in the second half of 2026, and on whether a shorter trip still clears the bar that the longer one is trying to clear at the same time.